Article Text
DTB select
Risk of serious adverse effects with Janus kinase inhibitors
Abstract
Overview of: European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. November 2022.
- Health Care Quality, Access, and Evaluation
- Drug-Related Side Effects and Adverse Reactions
Statistics from Altmetric.com
Footnotes
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.